ADC Collaborations

There are more than 15 collaborator ADC programs in clinical development using our technology.

Learn more

ADC Technology

Our pipeline of empowered antibody-based product candidates is based primarily on our ADC technology.

Learn more

A diversified product pipeline

We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our robust pipeline of empowered antibody-based therapies is designed to address significant unmet medical needs.

Program Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Approved
ADCETRIS® (brentuximab vedotin)
Relapsed Hodgkin lymphoma (HL)
Relapsed systemic anaplastic large cell lymphoma
HL post-autologous transplantation consolidation
Brentuximab Vedotin
ALCANZA: CD30-expressing cutaneous T-cell lymphoma (full data reported)
ECHELON-1: Frontline HL
(chemotherapy +/− brentuximab vedotin) (enrollment complete)
ECHELON-2: Frontline CD30-expressing mature T-cell lymphoma
(chemotherapy +/− brentuximab vedotin) (enrollment complete)
Relapsed CD30-expressing DLBCL (rituximab + bendamustine +/− brentuximab vedotin)
Frontline HL in patients 60+ (+/− chemotherapy or nivolumab)
Second-line HL
(+ nivolumab)
Relapsed NHL
(+ nivolumab)
Vadastuximab talirine
CASCADE: Frontline older acute myeloid leukemia (AML) (+HMAs)
Frontline myelodysplastic syndrome (MDS) (+ HMA)
Frontline younger AML
Denintuzumab mafodotin
Relapsed DLBCL (rituximab + chemotherapy +/− SGN-CD19A)
Frontline DLBCL
(+ chemotherapy)
Enfortumab vedotin*
Metastatic urothelial cancer
Metastatic breast cancer
Metastatic urothelial cancer
Advanced hematologic malignancies and solid tumors
Relapsed NHL
Relapsed AML
Relapsed multiple myeloma
Solid tumors
Relapsed multiple myeloma

*Co-development program with Astellas

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave